Health-related quality of life of patients with prostate cancer initiating GnRH agonist therapy: the PRISME study.

IF 2.7 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Aging Male Pub Date : 2024-12-01 Epub Date: 2024-10-04 DOI:10.1080/13685538.2024.2406547

François Rozet, Christophe Hennequin, Pierre Mongiat-Artus, Nathalie Pello-Leprince-Ringuet, Anne-Sophie Grandoulier, Morgan Roupret

{"title":"Health-related quality of life of patients with prostate cancer initiating GnRH agonist therapy: the PRISME study.","authors":"François Rozet, Christophe Hennequin, Pierre Mongiat-Artus, Nathalie Pello-Leprince-Ringuet, Anne-Sophie Grandoulier, Morgan Roupret","doi":"10.1080/13685538.2024.2406547","DOIUrl":null,"url":null,"abstract":"Objectives: To compare the evolution of health-related quality of life (HRQoL) over 6 months of GnRH agonist (GnRHa) therapy among age groups for patients with prostate cancer (PCa).Patients and methods: PRISME (NCT03516110) was a non-interventional, prospective study conducted in France in patients aged ≥60 years with PCa initiating GnRHa therapy within routine care. HRQoL was evaluated at baseline and after 6 months using the EORTC quality of life in ELDerly cancer patients 14 items (QLQ-ELD14) questionnaire. Cognitive status was assessed using the Mini Mental State Examination (MMSE). Analyses of covariance compared the evolution of the change from baseline of the QLQ-ELD14 scores among age groups.Results: 814 patients were enrolled (245, 60-70 years; 314, 70-75 years; 252, ≥75 years). Slight or no changes were observed in each QLQ-ELD14 dimension between baseline and 6 months, overall and by age. In the primary effectiveness analysis, there was no difference among age groups in the change from baseline in QLQ-ELD14 scores. Baseline cognitive status was lower in the oldest age group, but there were no changes in all age groups. As expected, sexual function declined in all age groups.Conclusion: GnRHa therapy influence on HRQoL, cognition and sexuality appeared independent of age.","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aging Male","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13685538.2024.2406547","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To compare the evolution of health-related quality of life (HRQoL) over 6 months of GnRH agonist (GnRHa) therapy among age groups for patients with prostate cancer (PCa).

Patients and methods: PRISME (NCT03516110) was a non-interventional, prospective study conducted in France in patients aged ≥60 years with PCa initiating GnRHa therapy within routine care. HRQoL was evaluated at baseline and after 6 months using the EORTC quality of life in ELDerly cancer patients 14 items (QLQ-ELD14) questionnaire. Cognitive status was assessed using the Mini Mental State Examination (MMSE). Analyses of covariance compared the evolution of the change from baseline of the QLQ-ELD14 scores among age groups.

Results: 814 patients were enrolled (245, 60-70 years; 314, 70-75 years; 252, ≥75 years). Slight or no changes were observed in each QLQ-ELD14 dimension between baseline and 6 months, overall and by age. In the primary effectiveness analysis, there was no difference among age groups in the change from baseline in QLQ-ELD14 scores. Baseline cognitive status was lower in the oldest age group, but there were no changes in all age groups. As expected, sexual function declined in all age groups.

Conclusion: GnRHa therapy influence on HRQoL, cognition and sexuality appeared independent of age.

查看原文本刊更多论文

开始接受 GnRH 激动剂治疗的前列腺癌患者的健康相关生活质量：PRISME 研究。

目的比较不同年龄组的前列腺癌（PCa）患者在接受 GnRH 促效剂（GnRHa）治疗 6 个月期间健康相关生活质量（HRQoL）的变化情况：PRISME (NCT03516110)是一项在法国进行的非干预性前瞻性研究，研究对象为年龄≥60岁、在常规治疗中开始接受GnRHa治疗的PCa患者。研究采用 EORTC ELDerly 癌症患者生活质量 14 项（QLQ-ELD14）问卷对基线和 6 个月后的 HRQoL 进行了评估。认知状况采用迷你精神状态检查（MMSE）进行评估。协方差分析比较了不同年龄组的 QLQ-ELD14 分数从基线开始的变化情况：结果：共有 814 名患者入选（245 人，60-70 岁；314 人，70-75 岁；252 人，≥75 岁）。从基线到 6 个月期间，QLQ-ELD14 的每个维度都有轻微变化或没有变化，总体上如此，各年龄组也是如此。在主要疗效分析中，不同年龄组的 QLQ-ELD14 分数与基线相比没有变化。最年长年龄组的基线认知状况较低，但所有年龄组均无变化。不出所料，所有年龄组的性功能都有所下降：结论：GnRHa疗法对HRQoL、认知能力和性能力的影响似乎与年龄无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Aging Male 医学-泌尿学与肾脏学

CiteScore

6.40

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： The Aging Male , the official journal of the International Society for the Study of the Aging Male, is a multidisciplinary publication covering all aspects of male health throughout the aging process. The Journal is a well-recognized and respected resource for anyone interested in keeping up to date with developments in this field. It is published quarterly in one volume per year. The Journal publishes original peer-reviewed research papers as well as review papers and other appropriate educational material that provide researchers with an integrated perspective on this new, emerging specialty. Areas of interest include, but are not limited to: Diagnosis and treatment of late-onset hypogonadism Metabolic syndrome and related conditions Treatment of erectile dysfunction and related disorders Prostate cancer and benign prostate hyperplasia.